Summary
This 8-K filing from Alnylam Pharmaceuticals, Inc. details the separation of its former Executive Vice President, Chief Legal Officer, and Secretary, Indrani L. Franchini, effective March 1, 2024. The company has entered into a separation and release agreement with Ms. Franchini, outlining the terms of her departure and ongoing engagement as a consultant. This agreement is significant for investors as it clarifies the financial and operational implications of a key executive's exit.
Key Highlights
- 1Indrani L. Franchini has transitioned from her role as EVP, Chief Legal Officer, and Secretary as of March 1, 2024.
- 2Alnylam has entered into a separation agreement with Ms. Franchini, providing for severance payments and other benefits.
- 3Severance includes approximately $597,000 (12 months base salary), a pro-rated annual incentive bonus for 2023, healthcare contributions, outplacement services, and legal fee reimbursement.
- 4Ms. Franchini will serve as a consultant to Alnylam for one year (until March 1, 2025), providing advisory services.
- 5Under the consulting agreement, outstanding unvested equity awards will continue to vest during the consulting period.
- 6Stock options will remain exercisable for three months post-consulting period.
- 7Ms. Franchini's equity awards will be treated similarly to active employees in the event of a change in control during the consulting period.
Frequently Asked Questions
The primary financial impact involves the severance package, estimated at $597,000 in base salary continuation, plus a pro-rated bonus, healthcare contributions, and legal fees. The ongoing consulting arrangement has a defined structure for compensation if hours exceed a certain threshold.
Ms. Franchini will provide consulting and advisory services for one year, which allows for continued input, particularly on legal matters. However, she is no longer in an executive officer role.
The continued vesting of Ms. Franchini's unvested equity awards during the consulting period means these awards will eventually become exercisable. This is a common practice to ensure a smooth transition and retain expertise, but it does represent potential future dilution for shareholders.
The consulting arrangement is designed to ensure a smooth transition of responsibilities from Ms. Franchini and to leverage her expertise for up to a year following her departure from the Chief Legal Officer role. This is common practice to maintain continuity on sensitive legal matters.